Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases

Video

Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Sabrina Serani
June 13th 2025
Article

Read More

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

Jordyn Sava;Aditya Bardia, MD, MPH
February 6th 2025
Podcast

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

Listen

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Adagrasib Plus Pembro Shows Promising First-Line Activity in KRAS G12C-Mutant NSCLC

Jordyn Sava
June 11th 2025
Article

Read More

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Juneja Explores AI’s Impact in Early Cancer Detection and Treatment

Jordyn Sava;Sanjay K. Juneja, MD
January 15th 2025
Podcast

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Listen

ELEVATE Trial: Elacestrant Combos Show Promise in ER+/HER2- Breast Cancer

ELEVATE Trial: Elacestrant Combos Show Promise in ER+/HER2- Breast Cancer

Chris Ryan
June 10th 2025
Article

The ELEVATE trial found combining elacestrant with everolimus or ribociclib is safe and effective for ER+/HER2- metastatic breast cancer.

Read More

Vepdegestrant Shows PFS Advantage in ESR1-Mutant ER+/HER2− Breast Cancer

Vepdegestrant Shows PFS Advantage in ESR1-Mutant ER+/HER2− Breast Cancer

Jordyn Sava
June 9th 2025
Article

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting its potential as a targeted treatment option.

Read More